IBA CE marks system to enhance anticancer proton therapy
This article was originally published in Clinica
Ion Beam Applications (IBA) has CE marked its second-generation Pencil Beam Scanning (PBS) system for sale in Europe. It is designed to enhance the performance of anticancer proton therapies, by producing a variable beam that narrows to 3mm, giving physicians greater dose control and allowing healthy tissue to be spared. The new system controls the dose across three dimensions, as opposed to photon-based intensity-modulated radiation therapy systems, which can only control two dimensions, IBA (Louvain-la-Neuve, Belgium) claims. Proton therapy is thought to be better than conventional photon radiotherapy, as it can target dosing more accurately and therefore decrease radiation exposure to healthy tissue. A prototype PBS device was cleared by the US FDA in 2008.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.